Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The complement system in central nervous system diseases.

H Rus1, F Niculescu

  • 1Department of Pathology, University of Maryland, School of Medicine, Baltimore 21201, USA. hrus@umaryland.edu

Immunologic Research
|August 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Multiple sclerosis (Houndmills, Basingstoke, England)·2010
Same author

Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.

Immunologic research·2001
Same author

C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis.

Glia·2000
Same author

Complement activation and atherosclerosis.

Molecular immunology·2000
Same author

Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation.

Journal of immunology (Baltimore, Md. : 1950)·1999
Same journal

Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study.

Immunologic research·2026
Same journal

Immunological spectrum in patients with thymoma: beyond good syndrome.

Immunologic research·2026
Same journal

Microbiome immune crosstalk in Sjögren's syndrome: mechanistic insights and translational perspectives.

Immunologic research·2026
Same journal

Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event.

Immunologic research·2026
Same journal

TRIM28 and TRIM32: multifaceted regulators of innate immunity and antiviral defence.

Immunologic research·2026
Same journal

Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.

Immunologic research·2026
See all related articles

The complement system, activated by factors like beta-amyloid, plays a key role in central nervous system (CNS) disorders. Complement activation damages neurons and affects oligodendrocyte (OLG) survival and differentiation.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • The complement system is implicated in inflammatory, neurodegenerative, and cerebrovascular diseases.
  • Astrocytes and neurons produce complement components, highlighting their role in CNS immunity.
  • Myelin and oligodendrocytes (OLG) can activate the complement cascade.

Purpose of the Study:

  • To investigate the role of complement activation and C5b-9 assembly in central nervous system (CNS) disorders.
  • To understand how complement affects oligodendrocyte (OLG) survival and phenotype.
  • To examine the impact of beta-amyloid on complement activation and neuronal damage.

Main Methods:

  • In vitro studies using myelin and oligodendrocytes (OLG).
  • Analysis of complement activation pathways, including the classical pathway.

Related Experiment Videos

  • Assessment of C5b-9 effects on OLG cell cycle, survival, and differentiation.
  • Evaluation of beta-amyloid as a complement activator.

    • Main Results:

    • Oligodendrocytes (OLG) activate the classical complement pathway without antibodies.
    • Sublytic C5b-9 promotes OLG survival, cell cycle activation, and proto-oncogene induction without causing cell death.
    • C5b-9 can reverse OLG differentiation and enhance cell survival.
    • Beta-amyloid protein activates the complement system, leading to bystander damage in neurons.

    Conclusions:

    • Complement activation and C5b-9 membrane assembly are significant contributors to the pathogenesis of CNS disorders.
    • Complement-mediated damage affects both neurons and oligodendrocytes (OLG), impacting CNS integrity.
    • These findings underscore the therapeutic potential of targeting the complement system in neurodegenerative and cerebrovascular diseases.